Skip to main content

Table 2 Baseline characteristics of patients with rheumatoid arthritis included in the study

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Variable All patients (n = 21,832) DMARDs (n = 5399) TNFi ± DMARDs (n = 13,367) Non-TNF biologics ± DMARDs (n = 2902) Tofacitinib ± DMARDs (n = 164)
Female sex, % 77.0 76.8 76.1 81.4 78.7
Age, years, median (IQR) 56 (48–63) 57 (49–63) 56 (48–63) 58 (50–65) 58 (50–64)
Year of cohort entry, %
 2011 48.5 25.9 52.3 70.5 0
 2012 21.6 27.2 20.5 14.1 0.6
 2013 14.7 21.9 13.1 8.7 43.9
 2014 15.2 25.0 14.1 6.7 55.5
Urban residency, % 82.6 81.1 83.2 82.8 89.4
Oral glucocorticoid use, %
 No use 32.3 29.2 33.4 33.0 31.0
  ≤ 7.5 mg/day of prednisone equivalent dose 63.0 65.1 62.2 62.2 64.9
  > 7.5 mg/day of prednisone equivalent dose 4.7 5.7 4.4 4.8 4.0
Nonsteroidal anti-inflammatory drug use, % 60.7 60.3 62.1 54.9 51.8
Selective COX-2 inhibitor use, % 12.8 10.9 12.9 16.0 13.4
Charlson comorbidity index, mean (SD) 0.61 (0.93) 0.73 (1.04) 0.54 (0.84) 0.73 (1.02) 0.86 (1.14)
Infection-related hospitalization, % 1.6 1.9 1.3 2.6 1.8
Number of emergency department visits, mean (SD) 0.44 (1.20) 0.48 (1.39) 0.42 (1.14) 0.44 (1.05) 0.43 (0.83)
Number of physician visits, mean (SD) 17.99 (13.26) 17.32 (14.07) 17.37 (12.24) 22.21 (15.24) 16.70 (14.24)
Number of rheumatology visits, mean (SD) 4.51 (4.92) 3.39 (3.85) 4.54 (4.71) 6.47 (6.75) 3.88 (3.26)
Number of hospitalizations, mean (SD) 0.16 (0.50) 0.16 (0.54) 0.14 (0.45) 0.23 (0.62) 0.17 (0.62)
  1. Abbreviations: DMARD Disease-modifying antirheumatic drug, TNFi Tumor necrosis factor inhibitor, COX-2 Cyclooxygenase-2
  2. Baseline variables were collected at cohort entry (sex, age, year of cohort entry, and place of residence) or 1 year prior to cohort entry (use of drugs, Charlson comorbidity index, hospitalized infection, and indicators of health service use)